JAK1 and dermatitis: PA-IL-32-AD-model was further subjected to different treatment in vivo, results of which showed that sh-JAK1 or miR-155 inhibitor effectively alleviated the development of specific dermatitis in PA-IL-32-AD-model, based on the skin inflammation clinical scores (Fig. 6A).